The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based…

Hengrui Pharma has lined up Bristol Myers Squibb as its latest partner in a deal worth up to $15.2 billion. The total value of the pact marks one of the largest East-to-West…